Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
KROS Stock Chart & Stats
$19.50
-$0.58(-3.66%)
At close: 4:00 PM EST
$19.50
-$0.58(-3.66%)
Day’s Range― - ―
52-Week Range$9.12 - $22.55
Previous CloseN/A
Volume109.28K
Average Volume (3M)636.32K
Market Cap
$575.20M
Enterprise Value-$33.38M
Total Cash (Recent Filing)$693.47M
Total Debt (Recent Filing)$17.43M
Price to Earnings (P/E)12.6
Beta0.77
Next Earnings
Mar 04, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding30,466,068
10 Day Avg. Volume359,759
30 Day Avg. Volume636,316
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)1.04
Price to Sales (P/S)166.94
P/FCF Ratio-3.64
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.14
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$21.20Price Target Upside8.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Balance SheetA strengthened balance sheet combined with an announced capital return program and substantial cash reserves supports continued funding of KER-065 development while reducing immediate dilution risk.
Clinical DataPhase 1 results for KER-065 demonstrated meaningful increases in lean mass, thigh muscle volume, bone density and bone formation markers, supporting the drug's potential to improve muscle and bone health.
Strategic PartnershipThe Takeda collaboration offers external validation of the Activin platform and creates potential milestone and royalty upside tied to elritercept's development and commercialization.
Bears Say
Pipeline SetbackDiscontinuation of cibotercept due to concerning pericardial effusions and insufficient topline data reduces pipeline diversification and underscores development and safety risks.
Regulatory TimingUnclear status of discussions with regulators creates uncertainty around the timing of Phase 2 initiation for KER-065 and could delay clinical progress and milestone realization.
Safety SignalA dose-dependent hemoglobin increase introduces uncertainty about KER-065's safety profile and may require additional monitoring, dose changes, or limitability in certain patient groups.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $9.12 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $575.20M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 49 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$1.135 by $0.955.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 30,466,068 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$1.135. Following the earnings report the stock price went up 3.323%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.20 (8.72% Upside)
$21.20 (8.72% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 655.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $180.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 15.7%
Last 30 Days ▲ 15.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.67%
12-Months-Change
Fundamentals
Return on Equity
10.43%
Trailing 12-Months
Asset Growth
28.23%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$21.20
▲(8.72% Upside)
Technical Analysis
Gyre Therapeutics
―
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---